Group of Independent Bioniche Shareholders Supports Board's Plan

MONTREAL, June 25, 2013 /CNW Telbec/ - Boeckh Investments Inc., a private company based in Montreal, today issued the following letter on behalf of a group of independent shareholders of Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC):

Dear fellow shareholders:

I am writing this letter on behalf of a group of independent shareholders of Bioniche Life Sciences Inc. Our own shareholdings, including affiliates, come to over 4 million shares. We have confirmed support for the views expressed in this letter from other independent shareholders owning or controlling over 12 million shares of Bioniche. Together, this group owns or controls over 16 million shares which represent approximately 15% of the outstanding shares of Bioniche.

The group wishes to inform the shareholder community that it supports the plan approved by the Board of Directors of Bioniche to sell the animal health business, subject to shareholder approval.  At the right price, Bioniche should be well-positioned to use the excess sale proceeds to exploit the global commercialization of Urocidin, which we believe has good potential.

Until the planned shareholder vote on November 5, 2013, Bioniche needs time to conduct a sound sale process without distraction.

This press release is not and does not constitute a solicitation of proxies.

Regards,

Ian Boeckh

Vice-President
Boeckh Investments Inc.

SOURCE: Boeckh Investments Inc.

For further information:

For more information or comments, please send emails to [email protected]